
Feature|Articles|June 9, 2025
- Vol 53 No 06
- Volume 53
- Issue 06
En bloc resection of bladder tumor: Is it the way forward?
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
"As urologists, we are the gatekeepers, and we must always perform the best possible surgery to optimize oncological outcomes," writes Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery).
Advertisement
Advertisement
More than 2 centuries ago, Philipp Bozzini invented the Lichtleiter, allowing urologists to visualize what is inside the bladder.1 About 1 century ago, Maximilian Stern invented the first resectoscope, which allows us to remove a bladder tumor with electrocautery.2 These 2 crucial elements empowered urologists to perform transurethral resection of bladder tumor (TURBT), a highly revolutionary approach given the limited resources that urologists had at that time.
Related to this article

Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.

Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.

CG Oncology plans to submit a second biologics license application to the FDA for cretostimogene in BCG-unresponsive NMIBC by the end of March 2027

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
Advertisement
Advertisement



